http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-1143727-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_27a71ddaaa2f5a8c228fc6cb3f3b3098 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D249-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D307-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D317-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D317-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D307-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D249-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-48 |
| filingDate | 1979-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1983-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ae061ab3f7cd8ad11023fb614b4fa07 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3e5d8324ccc10b9d5cd31e1c01f3f50c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_964aa1841dbe223cd0406120c1725857 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aca0bcce3226b4b6d3838b2ef3d5271a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09d695d998d309cfb4b64324c05b3564 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_81fe9984a7bc6171b3f87be46ea8e773 |
| publicationDate | 1983-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-1143727-A |
| titleOfInvention | Triazole derivatives |
| abstract | ABSTRACT The invention relates to compounds of the general formula (I) (I) and physiologically acceptable salts, hydrates and bioprecursors thereof, in which R1 and R2, which may be the same or different, each represent hydrogen, C1-10 alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, trifluoroalkyl or alkyl substituted by hydroxy, alkoxy, amino, alkylamino, dialkylamino or cycloalkyl, or R1 and R2 may together with the nitrogen atom to which they are attached form a 5 to 10 membered alicyclic heterocyclic ring which may be saturated or may contain at least one double bond, may be unsubstituted or may be substituted by one or more C1-3 alkyl groups or a hydroxy group and/or may contain another heteroatom; Alk represents a straight or branched alkylene chain of 1 to 6 carbon atoms; Q represents a furan or thiophen ring in which incorporation into the rest of the molecule is through bonds at the 2- and 5-positions, the furan ring optionally bearing a further substituent R7 adjacent to the group R1R2N-Alk-,or Q represents a benzene ring in which incorporation into the rest of the molecule is through bonds at the 1- and 3-positions; R7 represents halogen or C1-4 alkyl which may be substituted by hydroxy or C1-4 alkoxy; X represents -CH2-, , -O- or -S-where R6 represents hydrogen or methyl; n represents zero, 1 or 2; m represents 2, 3 or 4; R3 represents hydrogen, alkyl, alkenyl, aralkyl, hydroxyalkyl having at least two carbon atoms, alkoxyalkyl or aryl; and R4 and R5, which may be the same or different, each represent hydrogen, alkyl, alkyl substituted by hydroxy or C1-3 alkoxy, alkenyl, aralkyl or heteroaralkyl or R4 and R5 may together with the nitrogen atom to which they are attached form a 5 to 7-membered saturated heterocyclic ring which may contain another heteroatom, or the group , or R4 and R5 taken together may represent the group =CR8R9 where R8 represents aryl or heteroaryl and R9 represents hydrogen or alkyl. Preferably when X represents an oxygen atom or and n is zero, then Q only represents a benzene ring. The compounds of formula (I) show pharmacological activity as selective histamine H2-antagonists. |
| priorityDate | 1978-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 259.